Motley FoolTelix shares are up 98%: Is there more upside to come?
The bull case remains compelling: rapid growth, rising profits and broker optimism. The post Telix shares are up 98%: Is there more upside to come? appeared first on The Motley Fool Australia.
Telix Pharmaceuticals (TLX) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Google NewsTELIX Pharmaceuticals (ASX: TLX): Shares Edge Higher as Commercial Growth and Pipeline Progress Continue - Kalkine
TELIX Pharmaceuticals (ASX: TLX): Shares Edge Higher as Commercial Growth and Pipeline Progress Continue Kalkine
ASXTelix Completes Enrollment in Phase 3 BiPASS Study
other announcement
KalkineIs Putting Telix (ASX:TLX) on the Healthcare Stocks Radar?
Highlights Telix lifted half-year group revenue at a brisk rate against the prior corresponding period. Trading is tracking toward the upper end of the full-year revenue guidance range. Group gross margin improved, with precision medicine carrying the strongest margin profile. Telix Pharmaceuticals (ASX:TLX), the Melbourne-based radiopharmaceutical group whose imaging agents are used widely across United States cancer clinics, lifted half-year group revenue at a brisk clip and signalled it is...
Telix Pharmaceuticals Shares Hit A Wall of Resistance: What Happened? - thebull.com.au
Telix Pharmaceuticals Shares Hit A Wall of Resistance: What Happened? thebull.com.au
Telix Pharmaceuticals (ASX:TLX) Shares Cool As Profit Momentum Meets Pipeline Delays - simplywall.st
Telix Pharmaceuticals (ASX:TLX) Shares Cool As Profit Momentum Meets Pipeline Delays simplywall.st
Telix shares are tumbling. Is the stock finally at fair value?
Telix's sell-off reflects valuation, competition, and heightened growth expectations. The post Telix shares are tumbling. Is the stock finally at fair value? appeared first on The Motley Fool Australia.
Could Telix Pharmaceuticals’ Equity Facility Reshape Its Funding Strategy as the Pipeline Expands?
Highlights Telix Pharmaceuticals (ASX:TLX) has continued to report expanding revenue and stronger underlying operating performance from its precision medicine portfolio. Commercial momentum across prostate cancer imaging products is supporting the company as investment in its therapeutic pipeline continues. A newly established at-the-market equity facility provides Telix with an additional source of capital but introduces potential shareholder dilution. Regulatory developments across brain, kidn...
Telix Pharmaceuticals (ASX:TLX) The Business Is Profitable, So Why Raise More Equity? - Stocks Down Under
Telix Pharmaceuticals (ASX:TLX) The Business Is Profitable, So Why Raise More Equity? Stocks Down Under
Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress
The radiopharmaceuticals company has handed down its half-year results this morning. The post Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress appeared first on The Motley Fool Australia.
What Is Shaping Telix Pharmaceuticals (ASX:TLX) Now?
Highlights Telix Pharmaceuticals remains closely watched as the development and commercialisation of radiopharmaceutical products shapes its place within Australia's small-cap stocks landscape. Operational delivery, capital discipline and clear disclosure remain central to how the company's progress is assessed. Broader demand linked to interest in focused businesses that can expand from a narrower operating base continues influencing the sector conversation. Australia's sharemarket is moving...
How Is Telix Pharmaceuticals (ASX:TLX) Navigating Its Sector?
Highlights Telix Pharmaceuticals remains closely watched as the development and commercialisation of radiopharmaceutical products shapes its place within Australia's healthcare stocks landscape. Operational delivery, capital discipline and clear disclosure remain central to how the company's progress is assessed. Broader demand linked to ageing populations, improved diagnosis and demand for effective treatment pathways continues influencing the sector conversation. Australia's sharemarket is ...
Telix Pharmaceuticals Braces For Half-Year Results (ASX:TLX)
Highlights Telix Pharmaceuticals is due to release half-year results within days, drawing close attention after a volatile run for healthcare names. The radiopharmaceutical company has three theranostic candidates in pivotal-stage trials spanning prostate, kidney and brain cancer. A dedicated research and development day is also scheduled, giving the market a second near-term catalyst beyond the earnings release. Telix Pharmaceuticals (ASX:TLX) is heading into its half-year results release wi...
Telix Upsizes Bond as Precision Medicine Sales Climb (ASX:TLX)
Highlights A convertible bond offering was priced and upsized on strong demand, extending the group's financing maturity profile well into the next decade while supporting continued expansion of its precision medicine pipeline. Group revenue climbed at a rapid clip in the most recent quarter, tracking toward the upper end of full-year guidance and putting the group within reach of a landmark revenue level. Growth has been broad-based across the precision medicine portfolio, with the diagnostic ...
Telix (ASX:TLX) in Focus Before Half-Year Numbers
Highlights The radiopharmaceutical group has set a date for its half-year commercial update this week. Imaging product revenue has become the financial backbone of the wider business. Manufacturing and isotope logistics remain the defining operational challenge of the segment. Telix Pharmaceuticals (ASX:TLX), the Melbourne-headquartered radiopharmaceutical company that also carries a United States listing, moved into focus at the start of the week after confirming it will release half-year fi...
Telix Pharmaceuticals (ASX:TLX) Expands Radiopharmaceutical Pipeline Market
Highlights Article highlights the key aspects of company operations Strategic positioning supports long-term value creation Market opportunities drive growth and expansion This article covers telix pharmaceuticals expands (ASX:TLX) radiopharmaceutical pipeline on the ASX. The broader market context can also be viewed through the S&P/ASX All Technology Index, which tracks performance across relevant Australian-listed companies. Key Developments and Market Position Telix Pharmaceuticals d...
Telix Pharmaceuticals Ai-Driven (ASX:TLX) Drug Development Platform: Market
Highlights Article highlights the key aspects of company operations Strategic positioning supports long-term value creation Market opportunities drive growth and expansion This article covers telix pharmaceuticals ai-driven (ASX:TLX) drug development platform on the ASX. The broader market context can also be viewed through the S&P/ASX All Technology Index, which tracks performance across relevant Australian-listed companies. Key Developments and Market Position Telix Pharmaceuticals ap...
Why Telix Pharmaceuticals (ASX:TLX) Matters for Small-Cap Stocks Right Now?
Highlights Attention on Telix Pharma is shifting from broad headlines toward the mechanics of the business. The current smallcap stocks discussion includes funding runway, operating scale and competitive positioning. A clearer market narrative depends on consistent evidence across demand, delivery and financial flexibility. Australian equities are moving through a period in which sector labels alone explain less than they once did. Telix Pharmaceuticals (ASX:TLX) is being viewed through a sha...
Why Telix Pharmaceuticals (ASX:TLX) Could Be One to Watch Now?
Highlights Attention on Telix Pharma is shifting from broad headlines toward the mechanics of the business. The current penny stocks discussion includes funding discipline, operating scale and competitive positioning. A clearer market narrative depends on consistent evidence across demand, delivery and financial flexibility. Australian equities are moving through a period in which sector labels alone explain less than they once did. Telix Pharmaceuticals (ASX:TLX) is being viewed through a sh...
How Are Telix Pharmaceuticals (ASX:TLX), Neuren Pharmaceuticals (ASX:NEU), CLINUVEL (ASX:CUV) and PolyNovo (ASX:PNV) Responding to Sector Change?
Highlights Telix Pharmaceuticals and Neuren Pharmaceuticals are being assessed through operational delivery, strategic priorities and the quality of their underlying platforms. CLINUVEL and PolyNovo highlight how sector conditions can create different requirements across established and emerging business models. Capital discipline, customer relevance and consistent execution remain central as the four companies progress their current work programs. Australias market conversation is being shap...
Why Telix Pharmaceuticals (ASX:TLX) Continues to Capture Investors' Attention? - Kalkine
Why Telix Pharmaceuticals (ASX:TLX) Continues to Capture Investors' Attention? Kalkine
How Investors May Respond To Telix Pharmaceuticals (ASX:TLX) Upgraded FY26 Guidance And Pipeline Milestones - simplywall.st
How Investors May Respond To Telix Pharmaceuticals (ASX:TLX) Upgraded FY26 Guidance And Pipeline Milestones simplywall.st
How Is Telix (ASX:TLX) Framing the ASX Test?
Highlights Telix is being read through nuclear medicine scale as future leader positioning returns to local screens Fresh ASX sentiment is linking mid-tier companies drawing attention between defensive bluechips and volatile explorers with company-level execution rather than broad excitement Readers are focusing on global product demand and pipeline breadth without turning the sector story into instruction Telix is a radiopharmaceuticals company with diagnostic and therapeutic programs, which ...
Why Is Telix (ASX:TLX) Back on ASX Screens?
Highlights Telix is being read through nuclear medicine growth as defensive medical earnings returns to local screens Fresh ASX sentiment is linking healthcare returning to screens after softer inflation eased pressure on long-duration names with company-level execution rather than broad excitement Readers are focusing on global demand and regulatory execution without turning the sector story into instruction With offshore tech strength meeting domestic caution, Australian shares are being fil...
Telix H1 2026 Results - Investor Webcast Notification
other announcement
Telix Pharmaceuticals (ASX:TLX) Slips: What Are Investors Watching Beyond the Daily Move? - Kalkine
Telix Pharmaceuticals (ASX:TLX) Slips: What Are Investors Watching Beyond the Daily Move? Kalkine
Could Telix (ASX:TLX) Reset the Healthcare Stocks Debate?
Highlights Telix sits inside a sharper healthcare reset debate after health names working through a tougher year of valuation repair. Telixs position in the quality screen inside Healthcare Stocks rewards cleaner balance sheets, steadier revenue and credible execution. Healthcare Stocks around Telix remain tied to local rates, offshore leads and company-specific operating evidence. The Australian share market moved into today's session with a cleaner risk tone, and Cochlear (ASX:COH), a heari...
Could Telix (ASX:TLX) Be the Mid-Cap Signal the ASX Is Missing?
Highlights Telix frames the midcap stocks conversation as mid-sized companies are being measured against a reporting season that may reward cleaner delivery. Megaport adds a second ASX reference point as traders compare execution, balance-sheet quality and sector leadership below the mega caps. Radiopharmaceutical growth keeps the article focused on fresh market signals without drifting into directive language. Australia's share market is moving through a selective session, and Megaport (ASX:...
Can Telix (ASX:TLX) Keep Healthcare Attention?
Highlights Healthcare Stocks remain in focus as commercial healthcare momentum meets a selective Australian market Telix is being judged through healthcare stocks execution quality rather than market noise Fresh ASX themes point to proof, discipline and cleaner earnings narratives Healthcare has become a more selective trade as large defensive names, medical technology and radiopharmaceuticals all face different proof tests. Telix Pharmaceuticals (ASX:TLX), the radiopharmaceuticals company, gi...
Are Telix shares a buy, hold or sell following results?
This exciting healthcare stock is tipped to keep rising. The post Are Telix shares a buy, hold or sell following results? appeared first on The Motley Fool Australia.
Telix Pharmaceuticals (ASX:TLX): Why Is Radiopharma Proof In Focus?
Highlights Telix is being assessed through commercial evidence as the ASX market turns more selective. Healthcare Stocks attention is tied to continued attention on imaging agents and trial milestones and the wider reporting-season mood. The key debate is whether regulatory progress can support steadier confidence without relying on hype. The Australian share market has moved into a more selective phase, and Telix Pharmaceuticals (ASX:TLX) is drawing attention because a radiopharmaceuticals com...
Up 79% since February, why are Telix shares jumping higher again on Tuesday?
Investors are piling into Telix shares in Tuesday’s slumping market. But why? The post Up 79% since February, why are Telix shares jumping higher again on Tuesday? appeared first on The Motley Fool Australia.
Telix Pharmaceuticals: Q2 2026 revenue jumps 21%
Telix Pharmaceuticals also provided an update on its key clinical pipeline and new partnerships. The post Telix Pharmaceuticals: Q2 2026 revenue jumps 21% appeared first on The Motley Fool Australia.
Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress
earnings announcement
Why Are Telix Pharmaceuticals (ASX:TLX), Predictive Discovery (ASX:PDI) and GemLife Communities (ASX:GLF) in Focus?
Highlights Telix Pharmaceuticals (ASX:TLX) continues advancing its radiopharmaceutical portfolio across cancer diagnostics and therapies. Predictive Discovery (ASX:PDI) remains focused on progressing its flagship Bankan gold project in Guinea. GemLife Communities (ASX:GLF) continues expanding its land lease community portfolio to meet evolving housing demand. Companies with significant insider ownership often attract attention because leadership teams maintain a direct interest in long-term bus...
Down 9%: Is the rebound over for Telix shares?
Find out what brokers tip next for the ASX biopharmaceutical company. The post Down 9%: Is the rebound over for Telix shares? appeared first on The Motley Fool Australia.
Why Are Telix Pharmaceuticals (ASX:TLX) and Other Insider-Owned Growth Stocks in Focus?
Highlights Companies with meaningful insider ownership continue attracting attention as markets navigate volatile economic conditions. Telix Pharmaceuticals, Predictive Discovery and Lindian Resources are among the Australian companies highlighted for their growth outlooks. Investors are monitoring earnings potential, project execution and management alignment as key long-term considerations. Rising bond yields, evolving inflation expectations and shifting capital market conditions have increas...
Telix Pharmaceuticals (ASX:TLX) Move That Could Reshape Its Growth Story
Highlights Telix Pharmaceuticals strengthened its balance sheet through an upsized convertible bond raising with long-dated maturities. The funding comes as ASX Healthcare Stocks regain momentum following a broad sector recovery. The fresh capital provides greater flexibility to expand commercial operations and advance radiopharmaceutical programs. Australia's healthcare sector has returned to the spotlight as improving market sentiment lifts quality growth companies ...
Telix Pharmaceuticals (ASX:TLX) Pulls Back: Is the Healthcare Growth Trade Cooling? - Kalkine
Telix Pharmaceuticals (ASX:TLX) Pulls Back: Is the Healthcare Growth Trade Cooling? Kalkine
Telix Pharmaceuticals (ASX:TLX): Why Did This Radiopharmaceutical Company's Shares Come Under Pressure? - Kalkine
Telix Pharmaceuticals (ASX:TLX): Why Did This Radiopharmaceutical Company's Shares Come Under Pressure? Kalkine
Why Is Telix Pharmaceuticals (ASX:TLX) Quoting Additional Shares?
Highlights Telix Pharmaceuticals has applied to the ASX to quote additional ordinary fully paid shares. The newly quoted shares form part of the company's ongoing capital management activities. The application reflects continued corporate administration as Telix advances its global precision medicine strategy. Telix Pharmaceuticals Limited (ASX:TLX) has submitted an application to the Australian Securities Exchange to quote additional ordinary fully paid shares, conti...
Telix Pharmaceuticals (ASX:TLX) Slides Amid Healthcare Stocks Losing Momentum - Kalkine
Telix Pharmaceuticals (ASX:TLX) Slides Amid Healthcare Stocks Losing Momentum Kalkine
Why Is Telix Pharmaceuticals (ASX:TLX) Lifting Sentiment Across ASX Biotech Stocks?
Highlights Telix Pharmaceuticals has received positive FDA feedback supporting the next stage of its prostate cancer therapy programme. Imricor Medical Systems expanded the approved use of its MRI-guided cardiac ablation products in the United States. Recent regulatory progress continues strengthening confidence across Australia's healthcare and biotechnology sector. Telix Pharmaceuticals Ltd (ASX:TLX) has strengthened market confidence after receiving encouraging reg...
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention - Kalkine
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention Kalkine
FDA Alignment to Advance ProstACT Global Phase 3 Trial
other announcement
Up 44% year to date, how high could Telix shares go?
A recent presentation has impressed the brokers. The post Up 44% year to date, how high could Telix shares go? appeared first on The Motley Fool Australia.
Telix Pharmaceuticals Stock Leads 3 Australian Growth Picks With High Insider Ownership - simplywall.st
Telix Pharmaceuticals Stock Leads 3 Australian Growth Picks With High Insider Ownership simplywall.st